Navigation Links
Stereotaxis Reports Fourth Quarter and Full Year 2007 Financial Results
Date:3/3/2008

lization of the magnetic irrigated catheter, we anticipate strong demand for our system as well as an increase in utilization. In fact, at the eight European centers and one Canadian center that have participated in the external evaluation of the magnetic irrigated catheter, utilization increased to an average of 4.5 cases per week across these sites. The external evaluation by our catheter partner has involved roughly 250 cases and the results are currently being reviewed. We understand that a 94% acute success rate was achieved in these cases, with a high satisfaction rating by clinicians, and that there was only one minor and transient adverse event. We are proud of this exemplary safety record. In addition, the average economics per case from disposable revenue at these sites to Stereotaxis was approximately $1,000, which is the first time we have achieved this economic threshold. Overall, we are extremely pleased with the results.

"At the same time, the external evaluation phase of the launch has identified a relatively small number of catheters that exhibited signs of char or coagulum formation. Although it is our observation that changes in temperature setting and saline flow have largely resolved this issue in the clinical setting, our catheter partner has advised us that these characteristics are inconsistent with the product specifications. Consequently, they have informed us that they will be temporarily halting procedures done with magnetic irrigated catheters and will be delaying full commercialization until this issue, which is an extremely high priority for them, is resolved. Our catheter partner has attributed this issue to inconsistencies with specifications and this information, together with the observations of our own engineers, leads us to believe the root cause lies in the area of manufacturing conformance to specifications and should be addressable accordingly," Mr. Hogg stated.

Regarding the outlook for 2008, Mr. Hogg commented,
'/>"/>

SOURCE Stereotaxis, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Stereotaxis Appoints David Burkhardt, M.D. as Chief Medical Officer
2. Stereotaxis Announces FDA Approval of Its Partnered Magnetic Irrigated Catheter
3. Stereotaxis Niobe System Used to Perform More Than 10,000 Procedures Worldwide
4. Genetic Engineering & Biotechnology News reports on advances in miRNA
5. Rosetta Genomics Reports Fourth-Quarter and Full-Year 2007 Financial Results
6. Warner Chilcott Reports Operating Results for the Quarter and Year ended December 31, 2007
7. Cepheid Reports Fourth Quarter and Full Year 2007 Results
8. Strategic Diagnostics Reports Fourth Quarter and Full-Year Financial Results
9. US Oncology Reports Fourth Quarter and Fiscal Year 2007 Results
10. Barr Reports GAAP Earnings of $1.18 Per Share for 2007 and $0.30 Per Share for the Fourth Quarter; Adjusted Earnings Were $3.16 Per Share for 2007 and $0.79 Per Share for the Fourth Quarter
11. Masimo Reports Fourth Quarter 2007 and Full Year 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 15, 2014   Niagara Thermal Products is proud ... BioBlower Technologies LLC ("B3") as the critical thermal component ... from the Army Corps of Engineers.  B3 has developed ... biological contaminants and destroys VOCs and other chemical pollutants, ...
(Date:1/15/2014)... Toronto, Canada (PRWEB) January 15, 2014 ... perspectives on nonclinical and clinical safety assessment in biosimilars. ... a path for biosimilar drug development, however the complex ... regards to quality, safety and efficacy extremely challenging. Based ...
(Date:1/15/2014)... 15, 2014 DTS Language Services, Inc ... Web Portal for Life Science organizations who need document translations. ... subject matter of their documents in advance with a selection ... time-to-delivery of translations, often a critical factor in clinical and ...
(Date:1/14/2014)... Date: Friday, April 11, 2014 , Time: 6 p.m. – ... Warrington, Pa. , Details: The Hepatitis B Foundation, ... cure for hepatitis B and improving the quality of life ... on Friday, April 11 at Warrington Country Club in Warrington, ...
Breaking Biology Technology:Niagara Thermal Products LLC Selected as Critical Supplier for Buffalo BioBlower Air Purification Systems 2Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2DTS Improves Efficiency for Life Science Document Translations 2Hepatitis B Foundation to Host Annual Crystal Ball Gala 2
... to Exceed $8 Billion Globally by 2012VENTURA, Calif., ... a continuous, integrated and wearable remote patient monitoring ... executive officer Howard Baker will present at the ... the Marines Memorial Club and Hotel in San ...
... 7 Nuvelo, Inc.,(Nasdaq: NUVO ) ... approved,the issuance of Nuvelo Common Stock pursuant to ... between Nuvelo, ARCA biopharma and a Nuvelo,subsidiary. Nuvelo,s ... until January 23, 2009, to solicit additional proxies ...
... settled in for the,winter months and since the common ... days of school and work, now is the time ... Immunity Enhanced Beverage is designed,to do just that. , ... Products, Immunity Enhanced,Beverage is a ready-to-drink liquid supplement intended ...
Cached Biology Technology:VivoMetrics to Present at the 2009 Biotech Showcase 2VivoMetrics to Present at the 2009 Biotech Showcase 3Nuvelo Shareholders Approve Issuance of Common Stock Pursuant to Merger Agreement With ARCA biopharma 2Nuvelo Shareholders Approve Issuance of Common Stock Pursuant to Merger Agreement With ARCA biopharma 3Nuvelo Shareholders Approve Issuance of Common Stock Pursuant to Merger Agreement With ARCA biopharma 4Nuvelo Shareholders Approve Issuance of Common Stock Pursuant to Merger Agreement With ARCA biopharma 5Innovative Beverage Products Launches New Product Designed to Enhance the Body's Immune Defense 2
(Date:7/9/2014)... Emerging fungal pathogens pose a greater threat to ... declines of amphibians, bats, corals, bees and snakes. ... published in the prestigious journal Nature ... resistance to a deadly chytrid fungus implicated in ... is important because it is the basis of ...
(Date:7/9/2014)... Rochelle, NY, July 9, 2014Biofuels derived from the oils ... to fossil fuels. To achieve this goal, optimization of ... in open pond systems, is needed. Sapphire Energy has ... of open pond algae cultivation systems, described in ... Liebert, Inc., publishers. The article is available on the ...
(Date:7/9/2014)... The Cancer Genome Atlas (TCGA) Research Network have ... in lung adenocarcinoma, the most common subtype of ... expand the number of possible therapeutic targets for ... of patients with treatable mutations because many potent ... , TCGA is jointly funded and managed by ...
Breaking Biology News(10 mins):USF study: Amphibians can acquire resistance to deadly fungus 2Controlling contamination in open algae ponds for biofuels 2Study identifies novel genomic changes in the most common type of lung cancer 2Study identifies novel genomic changes in the most common type of lung cancer 3
... potentially life-threatening challenge characterized by pauses in breathing that ... prematurity (AOP) affects more than 50 percent of premature ... preemies. Caused in part by an underdeveloped central nervous ... womb, especially during sleep, AOP is not yet fully ...
... or the American Chemical Society as publisher of this report. ... time in the United States, researchers are reporting in a ... fresh and canned food as well as food wrapped in ... almost 1,000 times lower than the "tolerable daily intake" levels ...
... study by the team headed by Llus Ribas de Pouplana, ... Barcelona), has been chosen as "Paper of the week" in ... , which is already available online. The article describes the ... melanogaster (fruit fly) that is crucial for mitochondria. The ...
Cached Biology News:UMass Medical School study points to genetic link in apnea of prematurity 2Scientists at IRB Barcelona discover a new protein critical for mitochondria 2
DAPI: 4', 6-Diamino-2-phenylindole dihydrochloride. Antifade Solution: p-Phenylenediamine and glycerol in PBS solution. 0.4g/mL DAPI suspended in Antifade....
... 13(S)-HODE-d4 contains 4 deuterium atoms at the ... intended for use as an internal standard for ... spectrometry. 13(S)-HODE is produced by incubation of linoleic ... been shown to inhibit the adhesion of tumor ...
...
...
Biology Products: